Skip to main content
. Author manuscript; available in PMC: 2016 Nov 14.
Published in final edited form as: Biol Blood Marrow Transplant. 2016 May 14;22(8):1493–1503. doi: 10.1016/j.bbmt.2016.05.007

Table 5.

Risk factors to consider when screening for components of metabolic syndrome in transplant recipients

  • Personal history

  • Family history

  • Type of transplant (allogeneic or autologous)

  • TBI as part of pre-transplant conditioning

  • Development of acute or chronic GVHD

  • Ongoing therapy with corticosteroids

  • Ongoing therapy with calciunerin inhibitors

  • Ongoing therapy with sirolimus

  • Presence of additional metabolic syndrome components